Group 1 - The company, Bokan Vision Cloud-B (02592.HK), plans to globally offer 60.582 million shares, with 6.0585 million shares available in Hong Kong and 54.5235 million shares for international offering, at a price of HKD 10.10 per share [1] - The subscription period for the shares is from June 24 to June 27, 2025, with trading expected to commence on July 3, 2025 [1] - The company is a clinical-stage ophthalmic biotechnology firm focused on developing various therapies for eye diseases, with a history dating back to its establishment in 2015 [2] Group 2 - The company has two core products: CBT-001 for treating pterygium and CBT-009 for treating myopia in adolescents, with ongoing clinical trials for both products [2] - A cornerstone investment agreement has been established, with cornerstone investors agreeing to subscribe for shares totaling approximately HKD 179 million [3] - The estimated net proceeds from the global offering are approximately HKD 522.2 million, with 62.4% allocated for the continued clinical development of CBT-001 and 27.6% for CBT-009 [3]
拨康视云-B(02592.HK)预计7月3日上市 引入富策控股及Reynold Lemkins作为基石
Ge Long Hui·2025-06-23 22:53